Adjunctive use of statins for COVID-19
Loading...
Date
Authors
Sathekge, Mike Machaba
Byttebier, Geert
De Spiegeleer, Bart
Saxberg, Bo
Ueckermann, Veronica
Belmans, Luc
Alexander, Myriam
Fedson, David
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI
Abstract
The interaction between obesity, cardiometabolic disorders and COVID-19 represents a syndemic that requires both social intervention and a multipharmacological approach. The risks associated with diabetes, obesity and hypertension for severe COVID-19 may be confounded by the type of medication for these cardiometabolic factors. Furthermore, endothelial dysfunction is a common feature of the key comorbidities that increase risk for severe COVID-19 such as hypertension, obesity, diabetes mellitus, coronary artery disease or heart failure. Among the drugs used to manage hypertension and diabetes mellitus are angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and statins, all of which are known to improve endothelial dysfunction.
Description
Keywords
Obesity, Social intervention, Risks, COVID-19 pandemic, Coronavirus disease 2019 (COVID-19), Cardiometabolic disorders, Angiotensin-converting enzyme (ACE), Angiotensin receptor blockers (ARBs), Statins, Endothelial dysfunction
Sustainable Development Goals
Citation
Sathekge, M.; Byttebier, G.;
De Spiegeleer, B.; Saxberg, B.;
Ueckermann, V.; Belmans, L.;
Alexander, M.; Fedson, D. Adjunctive
Use of Statins for COVID-19. Journal of Clinical Medicine 2021, 10, 1407. https://DOI.org/10.3390/jcm10071407.